<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">31194320</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK542163</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2022</Year><Month>01</Month></PubDate><BeginningDate><Year>2022</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-34529">Felodipine</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Bansal</LastName><ForeName>Agam B.</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Cleveland Clinic, Ohio</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khandelwal</LastName><ForeName>Gaurav</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Aiims Bhopal</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText>Felodipine is a medication used in the management and treatment of essential hypertension. It is a member of the dihydropyridine class of calcium channel blockers. This activity describes the indications, action, and contraindications of felodipine as a valuable agent in treating essential hypertension. In addition, this activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for interprofessional team members in the treatment of patients with essential hypertension.</AbstractText><CopyrightInformation>Copyright © 2022, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-34529" sec="article-34529.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-34529" sec="article-34529.s2">Indications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-34529" sec="article-34529.s3">Mechanism of Action</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-34529" sec="article-34529.s4">Administration</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-34529" sec="article-34529.s5">Adverse Effects</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-34529" sec="article-34529.s6">Contraindications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-34529" sec="article-34529.s7">Monitoring</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-34529" sec="article-34529.s8">Toxicity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-34529" sec="article-34529.s9">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-34529" sec="article-34529.s10">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-34529" sec="article-34529.s11">References</SectionTitle></Section></Sections><ContributionDate><Year>2021</Year><Month>8</Month><Day>30</Day></ContributionDate><ReferenceList><Reference><Citation>Todd PA, Faulds D. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs. 1992 Aug;44(2):251-77.</Citation><ArticleIdList><ArticleId IdType="pubmed">1382018</ArticleId></ArticleIdList></Reference><Reference><Citation>Yedinak KC, Lopez LM. Felodipine: a new dihydropyridine calcium-channel antagonist. DICP. 1991 Nov;25(11):1193-206.</Citation><ArticleIdList><ArticleId IdType="pubmed">1763537</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz AM. Pharmacology and mechanisms of action of calcium-channel blockers. J Clin Hypertens. 1986 Sep;2(3 Suppl):28S-37S.</Citation><ArticleIdList><ArticleId IdType="pubmed">3540226</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhein S, Salameh A, Berkels R, Klaus W. Dual mode of action of dihydropyridine calcium antagonists: a role for nitric oxide. Drugs. 1999 Sep;58(3):397-404.</Citation><ArticleIdList><ArticleId IdType="pubmed">10493269</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunselman PH, Edgar B. Felodipine clinical pharmacokinetics. Clin Pharmacokinet. 1991 Dec;21(6):418-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">1782737</ArticleId></ArticleIdList></Reference><Reference><Citation>van Ree JW, van der Pol GA. Low dosages of felodipine ER once daily as monotherapy in elderly hypertensive patients: effect on ambulatory blood pressure and quality of life. J Hum Hypertens. 1996 Sep;10(9):613-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8953207</ArticleId></ArticleIdList></Reference><Reference><Citation>Regårdh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C. Pharmacokinetics of felodipine in patients with liver disease. Eur J Clin Pharmacol. 1989;36(5):473-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2753065</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson R, Karlberg BE, Gelin A, Aberg J, Regårdh CG. Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. J Clin Pharmacol. 1990 Nov;30(11):1020-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">2243149</ArticleId></ArticleIdList></Reference><Reference><Citation>Bratel T, Billing B, Dahlqvist R. Felodipine reduces the absorption of theophylline in man. Eur J Clin Pharmacol. 1989;36(5):481-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">2753066</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmfeldt D, Hedner T, Westerling S. Felodipine in hypertension--a review. J Cardiovasc Pharmacol. 1987;10 Suppl 1:S154-60.</Citation><ArticleIdList><ArticleId IdType="pubmed">2442509</ArticleId></ArticleIdList></Reference><Reference><Citation>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet] National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): 2017. Jan 11, Calcium Channel Blockers.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Proano L, Chiang WK, Wang RY. Calcium channel blocker overdose. Am J Emerg Med. 1995 Jul;13(4):444-50.</Citation><ArticleIdList><ArticleId IdType="pubmed">7605536</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene SL, Gawarammana I, Wood DM, Jones AL, Dargan PI. Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: a prospective observational study. Intensive Care Med. 2007 Nov;33(11):2019-24.</Citation><ArticleIdList><ArticleId IdType="pubmed">17622512</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31194320</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
